Category Archives: MS Treatment

Multiple Sclerosis and Prokarin - MS Treatment By: findjoymsrelief … Continue reading →

Peta Credlin has been one of the key figures behind the rise of Opposition Leader Tony Abbott. Photo: Alex Ellinghausen Labor has accused Tony Abbott of trying to jack up his standing with female voters after his top adviser, Peta Credlin, gave an unprecedented interview defending her boss against sexism claims and talking about her own IVF treatment. Ms Credlin, who is Mr Abbotts chief-of-staff, has taken the unusual step of speaking to womens magazine Marie Claire, describing her boss as deeply supportive of her efforts to have a child through IVF with her husband, Liberal Party federal director Brian Loughnane. The Liberal Party research must be showing that Mr Abbott does have a problem with women, and that he is trying to do something about it. This included keeping her fertility drugs in his parliamentary office fridge. Peta Credlin has revealed a battle to conceive a child through IVF. Photo: Andrew Meares The normally private Ms Credlin, 41, told the magazine Mr Abbotts views on abortion, contraception and IVF were far more balanced and nuanced than many people believe. Advertisement But Attorney-General Nicola Roxon said the Opposition Leader was clearly trying to fix his image problem with women. Australians … Continue reading →

The Kiwi mother of a seven-year-old British boy with cancer says she's doing the right thing launching another appeal to try to prevent him from having life-saving cancer treatment. New Zealand woman Sally Roberts, 37, told a British television program her fear of not becoming a grandmother was a factor in her decision to take further court action, just days before her son, Neon, is due to begin radiotherapy. Last month, High Court judge David Bodey rejected Ms Roberts' arguments that radiotherapy could cause Neon devastating harm, ruling the boy should undergo treatment on a cancerous brain tumour. Justice Bodey said Ms Roberts' judgment had "gone awry". However, Ms Roberts said she wouldn't even consider an appeal if she didn't think it was the best thing for Neon. "It should be my decision. I am the one that is going to be caring for him," she told ITV's Daybreak show. The treatment would damage Neon's DNA, affect his growth and leave him infertile, Ms Roberts said. "(Having) no grandchildren is a big factor." She said she wanted the opportunity to have alternative treatment options considered. Ms Roberts' estranged husband, Ben Roberts, has consented to radiotherapy treatment and currently has custody … Continue reading →

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rib-X Pharmaceuticals, Inc. announced today that Mary Szela has been appointed to its Board of Directors as its Chair. Ms. Szela brings her 25-year career as an accomplished pharmaceutical executive to this leadership role. "Mary Szela brings a wealth of talent and expertise to our team and is an outstanding choice to lead our Board of Directors, said Mark Leuchtenberger, Chief Executive Officer of Rib-X. Her broad commercial leadership experience will be particularly valuable as we continue to advance development of an urgently needed new antibiotic treatment option to patients and begin to consider options for launching the product. We look forward to working closely with Ms. Szela as we enter this exciting phase as a company and move ahead with our plans to initiate the Phase 3 program for delafloxacin for the treatment of acute bacterial skin and skin structure infections. With more than two decades in senior roles at Abbott Laboratories, Ms. Szela most recently served as Senior Vice President, Global Strategic Marketing and Services of the Pharmaceutical Products Group. Previously, she served as Senior Vice President of U.S. Pharmaceuticals, an $8 billion business. For over seven years, she directed the development, launch and … Continue reading →

Jan 4 2013 Multiple sclerosis patients in the Highlands are the first in Scotland to be offered a new drug treatment, a health board has said. Fingolimod, an oral treatment for a particular form of MS, was approved by the Scottish Medicines Consortium in September. It is designed to help patients with highly active relapsing remitting MS. Louise Smith, 47, from Thurso, was the first patient to start using Fingolimod, NHS Highland said. She was diagnosed with the condition more than four years ago. "To date, I have been treated with drug infusions as well as having to self-inject to prevent relapses," she said. "MS can take over so much of your life but I have set up my own business which means I can work flexibly. I do try and lead as normal a life as possible and this will definitely help. "Now I'm on the tablet I don't have to carry needles, I don't have to worry about where my medication can be stored and I don't have to think about going into hospital. It's only been a few weeks but so far so good." NHS Highland said a small number of patients are receiving the treatment which … Continue reading →

U.S. Secretary of State Hillary Rodham Clinton was released from a New York hospital on Wednesday, three days after doctors discovered a blood clot in her head. Ms. Clintons medical team advised her Wedneday evening that she was making good progress on all fronts and said they are confident she will fully recover, said Clinton spokesman Philippe Reines. Doctors had been treating Ms. Clinton with blood thinners to dissolve a clot in a vein that runs through the space between the brain and the skull behind the right ear. Shes eager to get back to the office, Mr. Reines said in a statement, adding that the secretary and her family are grateful for the excellent care she received at New York-Presbyterian Hospital. Mr. Reines said details of when Ms. Clinton will return to work will be clarified in the coming days. Ms. Clinton had been in the hospital since Sunday, when doctors discovered the clot during a follow-up exam stemming from a concussion she suffered earlier in December. While at home battling a stomach virus, Ms. Clinton had fainted, fallen and struck her head, a spokesman said. Grateful my Mom discharged from the hospital and is heading home, the secretarys … Continue reading →

TACOMA, Wash., Jan. 3, 2013 /PRNewswire/ --Results from a collaborative project between Revalesio and Dr. Kalipada Pahan at Rush University showed remarkable therapeutic activity of Revalesio's novel therapeutic RNS60 in a mouse model of multiple sclerosis (MS). In a study recently published in the journal PLOS ONE, RNS60 halted disease progression (as measured by progressive limb paralysis), prevented inflammation in the brain and spinal column while also protecting against demyelination, a process that makes nerve cells lose their protective covering. The research demonstrated that administration of RNS60 - either at early disease onset or late at the relapsing phase - halted disease progression. Animals treated with RNS60 were protected from infiltration of inflammatory cells to the central nervous system, and thus had a significant preservation of the protective nerve covering (myelin). The full details of the study can be found in the journal PLOS ONE (Protection of Tregs, Suppression of Th1 and Th17 Cells, and Amelioration of Experimental Allergic Encephalomyelitis by a Physically-Modified Saline - December 20, 2012). The study revealed further that RNS60 changed the over-reactive immune response associated with MS through increasing the population of regulatory T cells, which have protective function, while reducing the number of inflammatory … Continue reading →

By Jordo Bivona - December 24, 2012 | Tickers: BAX, BIIB, NVS, SNY | 0 Comments Jordo is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. Biogen Idec (NASDAQ: BIIB)is heavily focused on the treatment of multiple sclerosis (MS), and Avonex is one of the most prescribed treatments for relapsing forms of MS worldwide. Avonex is indicated for the treatment of patients with relapsing forms of MS to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. The company's other drug, Tysabri, is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, generally for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for highly active relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. Tysabri is marketed and distributed by Biogen Idec and Elan. Rituxan is another one of Biogen's marketed drugs and is the most prescribed treatment for non-Hodgkin's lymphoma. Biogen also … Continue reading →

New York, NY (PRWEB) December 27, 2012 MS research continued to advance on many fronts in 2012. This year saw: The National MS Society continues to propel research forward with a comprehensive strategy aimed at stopping MS, restoring function and ending MS forever (http://www.nationalmssociety.org/research/index.aspx): In the worlds largest meeting dedicated to MS research, over 7,000 scientists convened in Lyon, France to present findings at ECTRIMS (European Committee for Treatment and Research in MS). Over 1250 studies covering virtually every aspect of research were presented: Other important 2012 results toward stopping MS include: TREATMENT PIPELINE FDA Approves Oral Aubagio (Teriflunomide, Genzyme, a Sanofi company) The once-daily pill was approved as a disease-modifying therapy for relapsing forms of MS. Aubagio is the second oral disease-modifying therapy approved for the treatment of MS, and it became available for prescription in October 2012 in the U.S. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6864 Two potential therapies are before FDA Tysabri label updated to include lab test to enhance treatment decisions The test detects antibodies to the JC virus and can help determine a persons risk of developing PML, a severe brain infection that has emerged in some people who have taken Tysabri (natalizumab, Biogen Idec and Elan). The test should … Continue reading →

Part 2: Overview, Progress Toward Restoring Function and Ending MS NEW YORK, Dec. 27, 2012 /PRNewswire-USNewswire/ -- The National MS Society supported new and ongoing initiatives to propel efforts to restore function to people with MS through its Discovery and Fast Forward research programs. (Logo: http://photos.prnewswire.com/prnh/20090302/DC77093LOGO) PROGRESS TOWARD RESTORING FUNCTION LOST TO MS Other important 2012 results toward restoring function include: Nervous System Protection and Repair First trial of experimental anti-LINGO to stimulate myelin repair This first human phase I trial of BIIB033 (Biogen Idec), an immune antibody that inhibits LINGO-1, involved 64 healthy adult volunteers and 42 people with relapsing or secondary-progressive MS. There were no serious adverse events; headache was the most frequently adverse event reported. The authors concluded that the results support advancing this myelin repair strategy into a phase II clinical trial. Reported at the American Academy of Neurology annual meeting http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6377 Trial of patients' own adult stem cells appear safe and hints of benefit Researchers in the UK published results of a small clinical trial involving 10 people with secondary-progressive MS, reporting that injecting a person's own bone marrow stem cells appeared safe and possibly beneficial in helping to protect the nervous system from injury. … Continue reading →